BiologicalDrug
PF-06410293 clinical trials
Also written PF-06410293.
A product of Adalimumab; its studies count on that page too.
- studies test it
- 4
- open now
- 0
- in phase 3
- 2
- first study started
- 2013
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
4 studies that test it; most in 2013 (1)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Studies
Open first, then newest update. How each study uses PF-06410293 is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid ArthritisCompletedPhase 3PfizerNCT04230213Written as PF-06410293
- A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).CompletedPhase 3PfizerNCT02480153Written as PF-06410293
- A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))CompletedPhase 1PfizerNCT02237729Written as PF-06410293
- Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)CompletedPhase 1PfizerNCT01870986Written as PF-06410293